Valid for Submission
C92.51 is a billable diagnosis code used to specify a medical diagnosis of acute myelomonocytic leukemia, in remission. The code C92.51 is valid during the fiscal year 2021 from October 01, 2020 through September 30, 2021 for the submission of HIPAA-covered transactions.
The ICD-10-CM code C92.51 might also be used to specify conditions or terms like acute myeloid leukemia in remission, acute myelomonocytic leukemia, fab m4 or acute myelomonocytic leukemia, fab m4, in remission.
The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:
- Acute myeloid leukemia in remission
- Acute myelomonocytic leukemia, FAB M4
- Acute myelomonocytic leukemia, FAB M4, in remission
Diagnostic Related Groups - MS-DRG Mapping
Convert C92.51 to ICD-9 Code
The General Equivalency Mapping (GEM) crosswalk indicates an approximate mapping between the ICD-10 code C92.51 its ICD-9 equivalent. The approximate mapping means there is not an exact match between the ICD-10 code and the ICD-9 code and the mapped code is not a precise representation of the original code.
Information for Patients
Acute Myeloid Leukemia
Also called: AML, ANLL, Acute myelogenous leukemia
Leukemia is cancer of the white blood cells. White blood cells help your body fight infection. Your blood cells form in your bone marrow. In leukemia, however, the bone marrow produces abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work. In acute myeloid leukemia (AML), there are too many of a specific type of white blood cell called a myeloblast.
AML is the most common type of acute leukemia in adults. This type of cancer usually gets worse quickly if it is not treated. Possible risk factors include smoking, previous chemotherapy treatment, and exposure to radiation.
Symptoms of AML include:
- Shortness of breath
- Easy bruising or bleeding
- Bleeding under the skin
- Weakness or feeling tired
- Weight loss or loss of appetite
Tests that examine the blood and bone marrow diagnose AML. Treatments include chemotherapy, other drugs, radiation therapy, stem cell transplants, and targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells. Once the leukemia is in remission, you need additional treatment to make sure that it does not come back.
NIH: National Cancer Institute
- Acute myelogenous leukemia (AML) -- children (Medical Encyclopedia)
- Acute myeloid leukemia (Medical Encyclopedia)
- After chemotherapy - discharge (Medical Encyclopedia)
- Bone marrow transplant (Medical Encyclopedia)
- Bone marrow transplant - discharge (Medical Encyclopedia)
[Learn More in MedlinePlus]